The vector used in this new COVID-19 vaccine under accelerated development program is a deactivated rabies vaccine that is known to produce a strong immune response and is approved for the whole population including children and pregnant women, it said.
Kiran Mazumdar-Shaw said that the world is waiting for a vaccine for COVID-19 but till the time it is developed, there is a need to conduct tests and build a treatment regime to save lives. Indian biotech sector worked quickly and came out with indigenous test kits.
In order to urgently develop “safe and effective biomedical solutions” against Covid-19, the department of biotechnology (DBT) under science ministry has recommended 70 proposals from different institutions, including several IITs, JNU and Bennett University, for funding. These proposals are related to the development of vaccines, devices, diagnostics, therapeutics and other technological interventions.
This programme brings together academia — National Centre for Cell Science, Indian Institute of Technology, Indore, and industry – PredOmix Technologies and Bharat Biotech, in a collaborative mode for a public health emergency.
The EIR has been closed with a voluntary action indicated (VAI) classification for the observations, it added. As per the USFDA, a VAI means that objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
Until last month, polyester swabs were not manufactured in India and were imported from the US or China. With global demand for this product going up, it became difficult and more expensive to buy these swabs from either country.
Niti Aayog and the Department of Biotechnology have launched the Consortium for Affordable & Rapid Diagnostics (CARD) to scale up India’s capacity to make coronavirus testing kits. The move comes after India faced quality issues with Chinese-made antibody testing kits.
Biocon Executive Chairperson Kiran Mazumdar-Shaw has been recognised for her contribution to the world of medicine as an entrepreneur and innovative business leader, the Bengaluru-headquartered biopharmaceuticals company said in a statement.
The Indian Council of Medical Research has started analysing results from the evaluation of antibody test kits imported from China and will come out with its conclusions on their efficacy early next week, a senior government official told ET.
The ICMR has asked research institutions including hospitals to participate in the funding round and it expects research activities to take off by June.
Patients will swab their own nose using a testing kit sent by the company and will mail it in an insulated package back to the company.
The department of biotechnology has granted funds to 16 companies for developing drugs, vaccines and devices to fight the Covid-19 pandemic as India looks to speed up the process of tackling the disease.
The Indian Council of Medical Research on Tuesday advised states not to use the new rapid antibody test for Covid-19 from China till further notice after reports emerged that the kits are faulty. “The kits will be tested and validated in the field by our teams.
These kits, also known as serological testing kits, are not meant for early diagnosis or detection of the disease, said Raman Gangakhedkar, head of the department of epidemiology at the Indian Council of Medical Research.
In a memorandum dated April 1, the ministry of environment, forest and climate change relaxed the import policy to facilitate use of second-hand ventilators by hospitals.
A Kerala-based institute has developed a diagnostic test for Covid-19 which it claims can furnish results in less than half the time taken by the method currently being used in the country and for a fraction of its cost — ₹1,000.
Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service